|
| Author | Duration | Characteristics of participants | Interventions | Primary outcomes | Secondary outcomes |
|
| Poewe et al. [79] | (6 months) | N: 302; MFs. Mean duration of PD: 8.5 y | Pramipexole ( ) versus placebo ( ) | Disability; motor complications; on/off time | SE |
| Pahwa et al. [80, 81]; Sethi et al. [82, 83]; Stacy et al. [84]; Stocchi et al. [85, 86] | (24 weeks) | N: 393; MFs. Mean duration of PD: 8.6 y | Ropinirole (24-h) ( ) versus placebo ( ) | Disability; patient-rated QoL; on/off time; levodopa dose | SE
Depression sleep scales |
| Oertel et al. [87]; Pogarell et al. [88] | (32 weeks) | N: 363 (354 analysed); MFs. Mean duration of PD: 7.8 y | Pramipexole ( ) versus placebo ( ) | Disability; off time; levodopa dose | SE |
| Wong et al. [89] | (15 weeks) | N: 150; Mean duration of PD: 4.4 y | Pramipexole () versus placebo () | Disability; off time | SE |
| Musch and Bonura [90] | (24 weeks) | N: 218; on levodopa. Mean duration of PD: NA | Cabergoline ( ) versus placebo ( ) | Disability; off time; levodopa dose | SE |
| Pinter et al. [91] | (11 weeks) | N: 78; MFs. Mean duration of PD: 8.2 y | Pramipexole ( ) versus placebo ( ) | Disability; off time; levodopa dose | SE |
| Wermuth [92] | (12 weeks) | N: 69; MFs. Mean duration of PD: 10 y (range: 3–27 y) | Pramipexole ( ) versus placebo ( ) | Disability; motor complications; off time; levodopa dose | SE |
| Lieberman et al. [93]; Weiner et al. [94] | (32 weeks) | N: 360; MFs. Mean duration of PD: 9.2 y | Pramipexole ( ) versus placebo ( ) | Disability; on/off time; levodopa dose | SE |
| Guttman [95] | (9 months) | N: 247; MFs. Mean duration of PD: 7 y (range: 0.67–36 y) | Pramipexole ( ) versus bromocriptine ( ) versus placebo ( ) | Disability; off time | SE |
| Kreider et al. [96]; Lieberman et al. [97] | (6 months) | N: 149; predictable MFs. Mean duration of PD: 9 y | Ropinirole ( ) versus placebo ( ) | Disability; motor complications; off time; levodopa dose | SE |
| Rascol et al. [98, 99] | (12 weeks) | N: 46; not optimally controlled with levodopa. Mean duration of PD: 8 y | Ropinirole ( ) versus placebo ( ) | Disability; motor complications; off time | SE |
| Steiger et al. [100] | (6 months) | N: 37; MFs. Mean duration of PD: 12.8 y (range: 3–33 y) | Cabergoline () versus placebo () | Disability; motor complications; off time; levodopa dose | SE |
| Hutton et al. [101]; Lieberman and Hutton [102]; Schoenfelder et al. [103] | (24 weeks) | N: 188; MFs. Mean duration of PD: 10.6 y (range: 2–30 y) | Cabergoline ( ) versus placebo ( ) | Disability; on/off time; levodopa dose | SE |
| Olanow et al. [104] | (6 months) | N: 376; MFs. Mean duration of PD: 10.9 y | Pergolide ( ) versus placebo ( ) | Disability; motor complications; off time; levodopa dose | SE |
| Temlett et al. [105] | (5 weeks) | N: 44 (40 analysed); Mean duration of PD: 13.4 y | Bromocriptine () versus placebo () | Levodopa dose | SE |
| Toyokura et al. [106] | (8 weeks) | N: 222; not optimally controlled with levodopa. Mean duration of PD: 6.6 y | Bromocriptine ( ) versus placebo ( ) | Motor complications; on/off time | SE |
| Schneider and Fischer [107] | (4 weeks) | N: 40; not optimally controlled with levodopa. Mean duration of PD: 9.1 y | Bromocriptine () versus placebo () | On/off time; levodopa dose | |
| Jansen [108] | (5 months) | N: 23; not optimally controlled with levodopa. Mean duration of PD: 8.7 y | Bromocriptine () versus placebo () | Disability | |
|
